|
ATE260679T1
(de)
*
|
1992-04-03 |
2004-03-15 |
Univ California |
Selbstorganisierendes system zur verabreichung von polynukleotiden enthaltend ein amphiphatisches peptid
|
|
US5972883A
(en)
*
|
1993-03-16 |
1999-10-26 |
Yeda Research And Development Co. Ltd. |
Method for the treatment of neurodegenerative diseases by administering VIP, an analogue, fragment or a conjugate thereof
|
|
DE19536244A1
(de)
*
|
1994-09-30 |
1996-04-04 |
Juergen Dr Regenold |
Pharmazeutische Zusammensetzung zur lokalen Applikation
|
|
CA2167104A1
(en)
*
|
1995-01-17 |
1996-07-18 |
Joerg G.D. Birkmayer |
Nadh and nadph therapeutic agents for nasal, sublingual, rectal and dermal administration
|
|
US6051429A
(en)
|
1995-06-07 |
2000-04-18 |
Life Technologies, Inc. |
Peptide-enhanced cationic lipid transfections
|
|
JPH10212241A
(ja)
*
|
1996-05-27 |
1998-08-11 |
Sumitomo Pharmaceut Co Ltd |
Ｂｄｎｆを安定に含有する製剤
|
|
IS4516A
(is)
|
1997-07-01 |
1999-01-02 |
Gizurarson Sveinbjörn |
Nýtt lyfjaform
|
|
FR2771929B1
(fr)
*
|
1997-12-09 |
2001-02-23 |
Biovector Therapeutics |
Utilisation dans une composition pharmaceutique pour l'administration par voie nasale de particules hydrophiles pour la delivrance d'agents actifs au systeme nerveux central
|
|
AU757907B2
(en)
*
|
1998-09-03 |
2003-03-13 |
Neuren Pharmaceuticals Limited |
Neuroprotection
|
|
JP4854853B2
(ja)
|
1998-11-12 |
2012-01-18 |
ライフ テクノロジーズ コーポレーション |
トランスフェクション薬剤
|
|
ATE310501T1
(de)
*
|
1998-12-09 |
2005-12-15 |
Chiron Corp |
Verabreichung von neurotropischen wirkstoffen in das zentrale nervensystem
|
|
WO2001041732A1
(en)
*
|
1999-12-06 |
2001-06-14 |
Gore Stanley L |
Compositions and methods for intranasal delivery of active agents to the brain
|
|
EP1602378A1
(de)
*
|
1999-12-09 |
2005-12-07 |
Chiron Corporation |
Verfahren zur Verabreichung von Wirkstoffen in das zentrale Nervensystem oder Lymphsystem
|
|
JP2003516360A
(ja)
|
1999-12-09 |
2003-05-13 |
カイロン コーポレイション |
中枢神経系およびリンパ系に対するサイトカイン投与方法
|
|
DE10004547A1
(de)
*
|
2000-02-02 |
2001-08-09 |
Liedtke Pharmed Gmbh |
Verfahren zur selektiven Verabreichung zentralnervös aktiver Stoffe
|
|
US7084126B1
(en)
*
|
2000-05-01 |
2006-08-01 |
Healthpartners Research Foundation |
Methods and compositions for enhancing cellular function through protection of tissue components
|
|
US20020082215A1
(en)
*
|
2000-10-13 |
2002-06-27 |
Chiron Corporation |
Method for treating ischemic events affecting the central nervous system
|
|
US7766013B2
(en)
|
2001-06-05 |
2010-08-03 |
Alexza Pharmaceuticals, Inc. |
Aerosol generating method and device
|
|
US20070122353A1
(en)
|
2001-05-24 |
2007-05-31 |
Hale Ron L |
Drug condensation aerosols and kits
|
|
CA2446904A1
(en)
|
2001-05-24 |
2003-04-03 |
Alexza Molecular Delivery Corporation |
Delivery of drug esters through an inhalation route
|
|
US7458374B2
(en)
|
2002-05-13 |
2008-12-02 |
Alexza Pharmaceuticals, Inc. |
Method and apparatus for vaporizing a compound
|
|
US7090830B2
(en)
|
2001-05-24 |
2006-08-15 |
Alexza Pharmaceuticals, Inc. |
Drug condensation aerosols and kits
|
|
US7585493B2
(en)
|
2001-05-24 |
2009-09-08 |
Alexza Pharmaceuticals, Inc. |
Thin-film drug delivery article and method of use
|
|
WO2003057188A1
(en)
|
2001-11-21 |
2003-07-17 |
Alexza Molecular Delivery Corporation |
Delivery of caffeine through an inhalation route
|
|
US20040127409A1
(en)
*
|
2002-11-07 |
2004-07-01 |
Milkhaus Laboratory, Inc. |
Method of treatment of psychological conditions by administration of nerve growth factor
|
|
US8524899B2
(en)
|
2003-03-04 |
2013-09-03 |
California Institute Of Technology |
Alternative heterocycles for DNA recognition
|
|
JP4601619B2
(ja)
|
2003-05-21 |
2010-12-22 |
アレックザ ファーマシューティカルズ， インコーポレイテッド |
内蔵式加熱ユニットおよびそれを使用する薬剤供給ユニット
|
|
US7540286B2
(en)
|
2004-06-03 |
2009-06-02 |
Alexza Pharmaceuticals, Inc. |
Multiple dose condensation aerosol devices and methods of forming condensation aerosols
|
|
WO2006022714A1
(en)
|
2004-08-12 |
2006-03-02 |
Alexza Pharmaceuticals, Inc. |
Aerosol drug delivery device incorporating percussively activated heat packages
|
|
US7618615B2
(en)
|
2004-08-13 |
2009-11-17 |
Healthpartners Research Foundation |
Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
|
|
US9216161B2
(en)
|
2004-08-13 |
2015-12-22 |
Healthpartners Research Foundation |
Methods of treating Huntington's disease comprising administering metal chelators to the upper one-third of the nasal cavity
|
|
US7776312B2
(en)
|
2004-08-13 |
2010-08-17 |
Healthpartners Research Foundation |
Method of treating Alzheimer's disease comprising administering deferoxamine (DFO) to the upper one-third of the nasal cavity
|
|
US20090136505A1
(en)
|
2005-02-23 |
2009-05-28 |
Johanna Bentz |
Intranasal Administration of Active Agents to the Central Nervous System
|
|
CU23317A1
(es)
|
2005-07-22 |
2008-10-22 |
Ct De Investigacia N Y Desarro |
Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central
|
|
ATE458491T1
(de)
*
|
2005-08-26 |
2010-03-15 |
Univ Leland Stanford Junior |
Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin
|
|
US8153604B2
(en)
|
2006-04-24 |
2012-04-10 |
Geron Corporation |
CNS-tumor treatment method and composition
|
|
US20080216828A1
(en)
|
2007-03-09 |
2008-09-11 |
Alexza Pharmaceuticals, Inc. |
Heating unit for use in a drug delivery device
|
|
US8383865B2
(en)
|
2007-04-17 |
2013-02-26 |
Codman & Shurtleff, Inc. |
Curcumin derivatives
|
|
ES2562205T3
(es)
*
|
2007-04-17 |
2016-03-03 |
Codman & Shurtleff, Inc. |
Hibrídos de curcumina resveratrol
|
|
US9707274B2
(en)
|
2007-06-08 |
2017-07-18 |
Healthpartners Research & Education |
Methods for preventing and treating post-traumatic stress disorder (PTSD)
|
|
JP2010535198A
(ja)
*
|
2007-08-02 |
2010-11-18 |
ブッダ バイオファーマ オイ リミテッド |
コハク酸のコリン塩を含む鼻腔内投与用医薬品組成物
|
|
US7723515B1
(en)
|
2009-01-26 |
2010-05-25 |
Codman & Shurtleff, Inc. |
Methylene blue—curcumin analog for the treatment of alzheimer's disease
|
|
JP2014502953A
(ja)
*
|
2010-08-16 |
2014-02-06 |
ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク |
細胞透過性治療薬の鼻腔内送達
|
|
US8609088B2
(en)
|
2011-05-10 |
2013-12-17 |
Regents Of The University Of Minnesota |
Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
|
|
WO2012174481A1
(en)
|
2011-06-15 |
2012-12-20 |
Nerve Access, Inc. |
Pharmaceutical compositions for intranasal administration for the treatment of neurodegenerative disorders
|
|
DE102012015248A1
(de)
*
|
2012-08-05 |
2014-02-06 |
Naum Goldstein |
Verfahren zur Einbringung biologisch aktiver Substanzen ins Gehirn
|
|
US10279012B2
(en)
|
2013-03-11 |
2019-05-07 |
Healthpartners Research & Education |
Methods of treating and preventing social communication disorder in patients by intranasal administration of insulin
|
|
SG11201509419QA
(en)
|
2013-05-15 |
2015-12-30 |
Univ Minnesota |
Adeno-associated virus mediated gene transfer to the central nervous system
|
|
US10314911B2
(en)
|
2014-04-08 |
2019-06-11 |
Healthpartners Research & Education |
Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin
|
|
WO2015155544A1
(en)
*
|
2014-04-10 |
2015-10-15 |
Patrick Crowley |
Delivery of non-steroidal antiinflammatory agents to the brain via the nasal tract to treat neurological disorders
|
|
WO2016011203A1
(en)
|
2014-07-15 |
2016-01-21 |
Life Technologies Corporation |
Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
|
|
PL3242676T3
(pl)
|
2015-01-07 |
2024-07-15 |
Tonix Pharma Limited |
Preparaty oksytocyny zawierające magnez i sposoby ich stosowania
|
|
CN109414476B
(zh)
|
2016-04-12 |
2023-01-31 |
三叉神经股份公司 |
含镁催产素制剂和应用方法
|
|
IL262211B2
(en)
|
2016-04-15 |
2024-01-01 |
Univ Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type ii
|
|
CA3059449A1
(en)
|
2017-04-24 |
2018-11-01 |
Cocrystal Pharma, Inc. |
Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
|
|
KR20200024940A
(ko)
|
2017-07-27 |
2020-03-09 |
로커스 아이피 컴퍼니 엘엘씨 |
의약품, 보충제 및 섭취된 물질의 생체 이용률을 향상시키기 위한 조성물
|
|
AU2018335752A1
(en)
|
2017-09-22 |
2020-03-12 |
Christian HINDERER |
Gene therapy for treating Mucopolysaccharidosis type ii
|
|
EP3746138A4
(de)
|
2018-02-02 |
2021-11-03 |
Alexza Pharmaceuticals, Inc. |
Elektrische kondensationsaerosolvorrichtung
|
|
US20210121462A1
(en)
|
2018-07-27 |
2021-04-29 |
Cocrystal Pharma, Inc. |
Pyrrolo[2,3-b]pyridin derivatives as inhibitors of influenza virus replication
|
|
TWI844564B
(zh)
|
2018-09-10 |
2024-06-11 |
美商共結晶製藥公司 |
流感病毒複製之抑制劑
|
|
PL3866778T3
(pl)
|
2018-10-17 |
2023-03-27 |
Cocrystal Pharma, Inc. |
Kombinacje inhibitorów replikacji wirusa grypy
|
|
CA3118918A1
(en)
*
|
2018-11-05 |
2020-05-14 |
Rush University Medical Center |
Nasal delivery of low-dose aspirin for the treatment of neurodegenerative and lysosomal storage diseases
|
|
WO2020112716A1
(en)
|
2018-11-26 |
2020-06-04 |
Cocrystal Pharma, Inc. |
Inhibitors of influenza virus replication
|
|
CR20220103A
(es)
|
2019-08-10 |
2022-05-05 |
Locus Ip Co Llc |
Entrega olfatoria de compuestos terapéuticos al sistema nervioso central
|
|
US20230151034A1
(en)
|
2020-03-17 |
2023-05-18 |
Cocrystal Pharma, Inc. |
Peptidomimetic n5-methyl-n2-(nonanoyl-l-leucyl)-l-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds as inhibitors of norovirus and coronavirus replication
|
|
EP4132944A1
(de)
|
2020-04-10 |
2023-02-15 |
Cocrystal Pharma, Inc. |
Norovirus- und coronavirus-replikationshemmer
|
|
US20240398757A1
(en)
|
2021-08-03 |
2024-12-05 |
Cocrystal Pharma, Inc. |
Inhibitors for coronaviruses
|